SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-284038
Filing Date
2020-11-02
Accepted
2020-11-02 17:11:26
Documents
14
Period of Report
2020-11-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873214d8k.htm   iXBRL 8-K 26416
2 EX-99.1 d873214dex991.htm EX-99.1 10921
6 GRAPHIC g873214g1031090745158.jpg GRAPHIC 1899
  Complete submission text file 0001193125-20-284038.txt   163310

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fprx-20251102.xsd EX-101.SCH 3072
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20251102_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20251102_pre.xml EX-101.PRE 10954
7 EXTRACTED XBRL INSTANCE DOCUMENT d873214d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 201281236
SIC: 2834 Pharmaceutical Preparations